Any current/future new fundraising through debt or equity?

Anupam Rasayan plans to raise approximately INR 300 crores through non-convertible debentures (NCDs) to fund the Bliss GVS Pharma acquisition. The balance consideration for the acquisition will be funded via non-controlling, non-voting quasi-equity instruments which will be non-consolidating, non-dilutive, and non-participative. There is no mention of any immediate equity fundraising apart from the quasi-equity component related to the Bliss acquisition. The company does not envisage any major capex in the near future for existing plants; capex funding details are mostly related to strategic a

Future growth expectations in sales/revenue/volumes?

Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals. Order book at INR14,000 crores indicates potential INR1,700-1,800 crores additional incremental annual revenue mainly from agro and polymer segments. Pharma segment contribution has grown from near 0% to 20%, expected to continue strong organic growth domestically. Acquisitions of Bliss and Jayhawk add further growth from new customers and geographies including US, Europe, and India. Bliss currently operates at ~30% capacity utilizat

Future growth expectations in earnings/operating earnings/profits/EPS?

Anupam Rasayan expects a 20-30% CAGR growth over the next 3-5 years in standalone business revenues, driven primarily by Pharma and Polymer segments. Pharma revenue contribution has grown from near 0% to 20%, indicating stronger future earnings from this margin-accretive segment. Expansion in Bliss GVS Pharma is expected to boost revenue and profitability, leveraging under-utilized capacities (30% to 60-70%) and synergies with Anupam’s platform. Synergies from acquisitions like Bliss and Jayhawk will accelerate growth beyond organic expansion. EBITDA margins are expected to have an upward bias

Current/ Expected Orderbook/ Pending Orders?

Current order book stands at around INR 14,000 crores. On a 6 to 7-year average, the company anticipates adding INR 2,200 crores in incremental annual revenue from the existing pipeline. Of this incremental revenue, INR 1,700-1,800 crores is expected to come from agro and polymer segments. Additional new projects in the polymer business are expected to drive further growth. The pharma segment is also continuously growing organically, primarily from the Indian market. Synergies from acquisitions like Jayhawk and Bliss are expected to contribute additional growth on top of the stand-alone busine

IN US

Sale is live|00:00:00left today

Anupam Rasayan India LtdQ1 FY26Chemicals & Petrochemicals

Anupam Rasayan India Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,266P/E: 91.1Market Cap: ₹15.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals.
→Order book at INR14,000 crores indicates potential INR1,700-1,800 crores additional incremental annual revenue mainly from agro and polymer segments.
→Pharma segment contribution has grown from near 0% to 20%, expected to continue strong organic growth domestically.
→Acquisitions of Bliss and Jayhawk add further growth from new customers and geographies including US, Europe, and India.
→Bliss currently operates at ~30% capacity utilization, expected to ramp to 60%-70% driving revenue growth.
→The overall platform (Anupam + Tanfac + Jayhawk + Bliss) totals over INR4,000 crores in pro forma revenue, with potential for 5x expansion to ~$0.5 billion revenue.
→Cross-leveraging capabilities and customers across entities will boost growth synergies.

Margin guidance

Category 3

→Anupam Rasayan expects a 20-30% CAGR growth over the next 3-5 years in standalone business revenues, driven primarily by Pharma and Polymer segments.
→Pharma revenue contribution has grown from near 0% to 20%, indicating stronger future earnings from this margin-accretive segment.
→Expansion in Bliss GVS Pharma is expected to boost revenue and profitability, leveraging under-utilized capacities (30% to 60-70%) and synergies with Anupam’s platform.
→Synergies from acquisitions like Bliss and Jayhawk will accelerate growth beyond organic expansion.
→EBITDA margins are expected to have an upward bias due to increased Pharma and Polymer contribution.
→EBITDA margins stood around 23% for FY26, with expectations to maintain or slightly improve.
→Improvement in working capital management is expected to enhance operating cash flow.
→The Bliss acquisition is anticipated to be EPS accretive from day 1 of consolidation.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Anupam Rasayan plans to raise approximately INR 300 crores through non-convertible debentures (NCDs) to fund the Bliss GVS Pharma acquisition.
→The balance consideration for the acquisition will be funded via non-controlling, non-voting quasi-equity instruments which will be non-consolidating, non-dilutive, and non-participative.
→There is no mention of any immediate equity fundraising apart from the quasi-equity component related to the Bliss acquisition.
→The company does not envisage any major capex in the near future for existing plants; capex funding details are mostly related to strategic acquisitions.
→The debt profile currently includes around INR 1,500 crores gross debt, primarily working capital loan and term loan; the company believes current EBITDA supports comfortable debt levels.

Order book

Yes

→Current order book stands at around INR 14,000 crores.
→On a 6 to 7-year average, the company anticipates adding INR 2,200 crores in incremental annual revenue from the existing pipeline.
→Of this incremental revenue, INR 1,700-1,800 crores is expected to come from agro and polymer segments.
→Additional new projects in the polymer business are expected to drive further growth.
→The pharma segment is also continuously growing organically, primarily from the Indian market.
→Synergies from acquisitions like Jayhawk and Bliss are expected to contribute additional growth on top of the stand-alone business.
→A growth rate of 20-30% CAGR over the next 3 to 5 years is envisaged based on the strong order book and pipeline.

Capex plans

Yes

- Ongoing INR250 crores capex at Halol facility is for the CDMO business tied to a major multinational pharma client; it is separate from other plant capex and has a longer gestation period with expected 4x-5x asset turnover. - Stand-alone operations at Anupam have no major incremental capex planned; maintenance capex expected around INR50-75 crores annually over next 2-3 years. - Last year, Anupam completed a capex program with INR315 crores spent; all plants now commercialized. - No major near-term capex is envisaged for current capacity which sufficiently supports near-term growth. - Integration with Bliss and Jayhawk will focus on leveraging existing capacities rather than merging or consolidating plants, so no immediate large capex indicated there. Overall, focus is on utilizing existing capacities, targeted maintenance capex, and select strategic capex like Halol for CDMO expansion.

How does Anupam Rasayan India Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Anupam Rasayan India Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Anupam Rasayan India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio